Cannabis extract trial offers new hope for controlling severe epilepsy
NCT ID NCT07403266
Summary
This study is testing whether a full-spectrum cannabis extract called YCJ-01 can safely reduce the number of seizures in people with Tuberous Sclerosis Complex (TSC) whose epilepsy is not controlled by standard treatments. It is a Phase 3 trial enrolling 84 participants, aged 2 to 65, who will receive either the study medicine or a placebo to compare results. The main goal is to see if the treatment can significantly lower monthly seizure counts and improve seizure control for this challenging condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBEROUS SCLEROSIS COMPLEX (TSC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Ruber Internacional
RECRUITINGMadrid, 28034, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.